A new phase of GLP-1 research is underway. Researchers are preparing to test a semaglutide implant placed under the skin, rather than delivered through a weekly injection. The study is set to begin in 2026 and will look at how the body handles this new delivery method. For anyone who takes semaglutide by injection, this trial is an early signal of how treatment might change in the future.
The trial is registered as a Phase 1 study and has not yet begun recruiting participants, which means it is still in the early planning stage. Phase 1 studies focus on safety, tolerability, and how a drug moves through the body, rather than on whether it works better than existing options. In this case, researchers will study how a semaglutide implant behaves once it is placed under the skin, including how the drug is released and absorbed over time. Because this is the first time this delivery method will be tested in people, the results will only tell us whether an implant is safe to continue studying, not whether it will replace weekly injections. It may be years before this method reaches wider use, if it is approved at all.
If you currently manage your GLP-1 treatment through weekly injections, this trial is not something to act on yet. It is a research study, not a treatment option, and it will take time before any results are available. You may want to keep an eye on how the study progresses and ask your prescriber about new developments if you are curious. In the meantime, continue following the treatment plan you and your doctor have already agreed on.
Key details
A semaglutide implant placed under the skin enters its first human safety trial in 2026,…
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-06-29